GBM Study Group Bioanalytics Workshop

Translational Protein Biomarkers:

Impact in Drug Development and Safety

Leading Experts Cutting-Edge Science Real World Impact

Join international leaders from academia, industry, and regulatory science as they explore the latest advances in biomarker discovery, validation, and clinical implementation

DATE
17 and 18-Sep-2026

VENUE
NMI Natural and Medical Sciences Institute
at the University of Tübingen
Markwiesenstrasse 55, 72770 Reutlingen

ORGANIZER
GBM, NMI
& SIGNATOPE GmbH

INSPIRING TALKS. BROAD PERSPECTIVES

Prof. Dr. Christoph Borchers
(Jewish General Hospital, Montreal, CAN)
SysQuan: Affordable Absolute Quantification of the Entire Mouse and Human Proteome

Dr. Warren Glaab
(Merck Sharp & Dohme, West Point, PA)
Current Application of Emerging Skeletal Muscle and Liver Safety Biomarkers for Monitoring Drug-Induced Skeletal Muscle and Liver Injury in Early Clinical Trials

Dr. Ulrich Kunz
(Boehringer Ingelheim, Biberach, GER)
The importance of Context of Use Definition for Biomarker Measurement in Clinical Trials

Dr. med. Klemens Ruprecht
(University of Heidelberg, Heidelberg, GER)
Blood-Based Biomarkers in Neuroimmunology: Recent Progress and Perspectives

Dr. Dr. med. Susanne Roth
(University Hospital Tübingen, Tuebingen, GER)
Risk Prediction of Intraductal Papillary Mucinous Neoplasm Based on Clinical & Serum Markers

Prof. Dr. Jochen Schwenk
(KTH Royal Institute of Technology, Stockholm, SE)
Self-Sampled Blood Proteomics Reveals Molecular Health Dynamics

Prof. Dr. Chris Goldring
(University of Liverpool, Liverpool, GB)
Biomarkers and Humanised Models for Safer Medicine

Dr. Marcus Bantscheff
(Roche, Basel, CH)
Pharmacoproteomics Profiling Identifies Secreted Markers of Drug Action

Dr. Gary Friedman
(CRITICAL-PATH Institute, Tucson, AZ)
Using Precedent Biomarker Qualifications to Support Not-Yet- Qualified Kidney Injury Biomarker-Current Status

Dr. Jens Göpfert
(NMI, Reutlingen, GER)
Hidden Pitfalls in Biomarker Immunoassays: Lessons from Clinical Study Implementation

Dr. Annika Nelde
(University Hospital Tübingen, Tuebingen, GER)
Peptide-based Immunotherapy – Bench to Bedside Developments

Dr. Oliver Pötz
(SIGNATOPE GmbH, Reutlingen,GER)
TransBioLine Wrap-Up: Advancing Translational Protein Safety Biomarkers for Drug-Induced Organ Injury

Dr. Markus Templin
(NMI, Reutlingen, GER)
Signaling Network Profiling for Patient Stratification and Drug Target Evaluation

Organized by GBM SIGNATOPE NMI Natural and Medical Sciences Institute

Supported by BRUKER Luminex

BE PART OF THE DISCUSSION
Register now and secure your spot

More information and registration